Autoimmunity in human primary immunodeficiency diseases

被引:144
作者
Arkwright, PD
Abinun, M
Cant, AJ
机构
[1] Univ Manchester, St Marys Hosp, Acad Unit Child Hlth, Manchester M13 0JH, Lancs, England
[2] Newcastle Gen Hosp, Paediat Immunol & Infect Dis Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
关键词
D O I
10.1182/blood.V99.8.2694
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human primary immunodeficiency diseases are experiments of nature characterized by an Increased susceptibility to Infection. In many cases, they are also associated with troublesome and sometimes life-threatening autolmmune complications. In the past few years, great strides have been made In understanding the molecular basis of primary immunodeficiencies, and this had led to more focused and successful treatment. This review has 3 aims: (1) to highlight the variety of autoimmune phenomena associated with human primary immunodeficiency diseases; (2) to explore how primary immunodeficiencies predispose patients to autolmmune phenomena triggered by opportunistic infections; and (3) to consider the rationale for the current treatment strategies for autoimmune phenomena, specifically in relation to primary immunodeficiency diseases. Reviewing recent advances In our understanding of the small subgroup of patients with defined causes for their autoimmunity may lead to the development of more effective treatment strategies for Idiopathic human autolmmune diseases. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:2694 / 2702
页数:9
相关论文
共 128 条
  • [51] MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENCY - CLINICAL MANIFESTATIONS, IMMUNOLOGICAL FEATURES, AND OUTCOME
    KLEIN, C
    LISOWSKAGROSPIERRE, B
    LEDEIST, F
    FISCHER, A
    GRISCELLI, C
    [J]. JOURNAL OF PEDIATRICS, 1993, 123 (06) : 921 - 928
  • [52] CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
    Kuehnie, I
    Huls, MH
    Liu, ZS
    Semmelmann, M
    Krance, RA
    Brenner, MK
    Rooney, CM
    Heslop, HE
    [J]. BLOOD, 2000, 95 (04) : 1502 - 1505
  • [53] Lacroix-Desmazes S, 1999, J IMMUNOL, V162, P5601
  • [54] Levy A, 1997, AM J MED GENET, V69, P356, DOI 10.1002/(SICI)1096-8628(19970414)69:4<356::AID-AJMG4>3.0.CO
  • [55] 2-J
  • [56] Clinical spectrum of X-linked hyper-IgM syndrome
    Levy, J
    EspanolBoren, T
    Thomas, C
    Fischer, A
    Tovo, P
    Bordigoni, P
    Resnick, I
    Fasth, A
    Baer, M
    Gomez, L
    Sanders, EAM
    Tabone, MD
    Plantaz, D
    Etzioni, A
    Monafo, V
    Abinun, M
    Hammarstrom, L
    Abrahamsen, T
    Jones, A
    Finn, A
    Klemola, T
    DeVries, E
    Sanal, O
    Peitsch, MC
    Notarangelo, LD
    [J]. JOURNAL OF PEDIATRICS, 1997, 131 (01) : 47 - 54
  • [57] SELECTIVE IGA DEFICIENCY AND AUTOIMMUNITY
    LIBLAU, RS
    BACH, JF
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1992, 99 (01) : 16 - 27
  • [58] Immunology of chronic mucocutaneous candidiasis
    Lilic, D
    Gravenor, I
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (02) : 81 - 83
  • [59] IgA deficiency: what we should - or should not - be doing
    Lilic, D
    Sewell, WAC
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (05) : 337 - 338
  • [60] LIPFORD EH, 1988, BLOOD, V72, P1674